GlassScriptPhysician profile
Reni A Grimes
NPI 1285877837
$1,194.78
in general payments reported to CMS, 2019-2025
23 companies · $52.28 in 2025
The $52.28 reported for 2025 was less than what a typical Anatomic Pathology & Clinical Pathology provider received nationally (typical 2025 total: $50.59).
See the full distribution for Anatomic Pathology & Clinical Pathology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $407 · 2020: $95.00 · 2021: $264 · 2022: $224 · 2023: $71.85 · 2024: $80.54 · 2025: $52.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $204.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $263.25 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $141.14 | 2019-2021 | |
| Amgen INC. | $135.15 | 2019-2022 | |
| Lilly USA, LLC | $121.36 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $72.80 | 2021-2025 | Prevymis |
| Puma Biotechnology, INC. | $59.29 | 2021-2023 | |
| Seagen INC. | $54.97 | 2021-2023 | Tukysa, Adcetris |
| Sun Pharmaceutical Industries INC. | $44.27 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $43.92 | 2022 | |
| Eisai INC. | $38.20 | 2019 | |
| Novo Nordisk INC | $36.90 | 2019 | |
| Abbvie INC. | $21.91 | 2024 | |
| Abbott Laboratories | $18.93 | 2025 | Alinity M |
| Glaxosmithkline, LLC. | $17.72 | 2021 | |
| Siemens Medical Solutions USA, INC. | $17.36 | 2025 | Atellica Ch 930 Analyzer |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $15.27 | 2020 | |
| Genentech USA, INC. | $14.79 | 2024 | Polivy |
| Beckman Coulter, INC. | $14.59 | 2022 | |
| Celgene Corporation | $14.34 | 2019 | |
| Btg International INC. | $12.83 | 2019 | |
| Foundation Medicine, INC. | $12.75 | 2021 | |
| Verastem, INC. | $11.54 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reni Grimes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.